CorMedix (CRMD) Corporate presentation summary

Business overview and strategy

• Focuses on innovative specialty injectable therapies for institutional markets, with a scalable commercial platform and diversified product portfolio including DefenCath, REZZAYO, and six anti-infectives.

• Revenue guidance for 2026 is $325–345 million, with adjusted EBITDA projected at $125–140 million.

• Products are sold to over 500 hospitals, infusion centers, and clinics, supported by an integrated commercial team.

• Growth driven by pipeline expansion, label extensions, and government partnerships.

• Strategic flexibility for bolt-on acquisitions and organic growth.

Leadership and operational strength

• Leadership team has a strong track record in commercial execution and clinical development.

• Executives bring experience from major pharma and biotech firms, covering commercial, financial, legal, and business development roles.

Financial highlights

• As of June 30, 2026, cash and short-term investments total $257 million, with convertible debt at $150 million.

• FY 2025 pro forma net revenue was $401 million; Q2 2026 net revenue reached $102 million.

• FY 2026 revenue guidance is $325–345 million, with DefenCath sales expected at $100–140 million.